Wednesday, June 19, 2013

Partnerships Session Spotlight: Turning Potential into Reality within Asia Pacific: Examining the Relationship between Commercial Viability and Clinical Research Activity

The commercial viability of any market enables a given company to distribute innovative medicines to those in need. This viability is reliant upon government regulation, healthcare access, patient populations, and many more market access factors. When a company is determining the safety and efficacy of a product in development, a commitment must be made to conducting research throughout various regions and countries. How big a factor is long-term commercial access to this development decision-making?

We'll be addressing this at the Partnerships in Clinical Trials Asia conference during the session Turning Potential into Reality within Asia Pacific: Examining the Relationship between Commercial Viability and Clinical Research Activity taking place September 4-6, 2013 in Shanghai, China.  For more information on this session and the rest of the program, download the agenda.  If you'd  like to join us, as a reader of this blog when you register to join us and mention code XP1875BLOG, you'll save 15% off the standard rate.

Featured session: Turning Potential into Reality within Asia Pacific: Examining the Relationship between Commercial Viability and Clinical Research Activity

Featured Panelists: 
Dr. Jason Mann, Managing Director, KONUS CAPITAL, HONG KONG, Moderator
Dr. Jonathan Wang, Senior Managing Director, ORBIMED ASIA, CHINA, Panelist
Dr. Michael Choy, Principal, THE BOSTON CONSULTING GROUP, CHINA, Panelist
Dr. Johnson Lau, Executive Chairman, KINEX PHARMACEUTICALS, Executive Chairman, XBL – CHINA, XENOBIOTIC LABORATORIES, USA, Panelist
Dr. Marcus Klein, Senior Director, Regional Medical Officer, J-APAC, GENZYME SANOFI-AVENTIS, SINGAPORE, Panelist
Cory Williams, Head, Strategy & Project Management, PFIZER, CHINA, Panelist
Samantha Du, Managing Director, SEQUOIA CAPITAL, CHINA, Panelist

Discussions during the presentation include:
  • • The progression of Asia’s national healthcare infrastructures and effect on long-term commercial viability 
  • • The prevalence of local hospitals and clinics for driving both access and innovation
  • • The industry’s commercial and R&D growth in the region
  • • Evaluating how global population needs over the next 10 years will influence the nature of conducting trials and its implications in Asia




No comments: